ID   UT-SCC-19A
AC   CVCL_7816
SY   UTSCC19A; University of Turku-Squamous Cell Carcinoma-19A
DR   cancercelllines; CVCL_7816
DR   GEO; GSM2883361
DR   GEO; GSM2888824
DR   IARC_TP53; 11061
DR   Wikidata; Q54992077
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=8782485;
RX   PubMed=15287027;
RX   PubMed=16715129;
RX   PubMed=17312569;
RX   PubMed=26694163;
RX   PubMed=29970484;
RX   PubMed=30135316;
RX   PubMed=33802339;
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=8782485; PubMed=15287027; PubMed=33802339).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Larynx, glottis; UBERON=UBERON_0002486.
ST   Source(s): PubMed=30135316; PubMed=33802339
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12,13
ST   D16S539: 12,13
ST   D18S51: 16
ST   D19S433: 13.2,18.2
ST   D21S11: 30,32.2
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 10,14
ST   FGA: 24
ST   TH01: 6
ST   TPOX: 8,10
ST   vWA: 14,19
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7817 ! UT-SCC-19B
SX   Male
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 16
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x;
RA   Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O.,
RA   Rytomaa T.;
RT   "p53 mutations associated with increased sensitivity to ionizing
RT   radiation in human head and neck cancer cell lines.";
RL   Cell Prolif. 29:219-230(1996).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=16715129; DOI=10.1038/sj.onc.1209690;
RA   Jarvinen A.-K., Autio R., Haapa-Paananen S., Wolf M., Saarela M.,
RA   Grenman R., Leivo I., Kallioniemi O.-P., Makitie A.A., Monni O.;
RT   "Identification of target genes in laryngeal squamous cell carcinoma
RT   by high-resolution copy number and gene expression microarray
RT   analyses.";
RL   Oncogene 25:6997-7008(2006).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=26694163; DOI=10.1371/journal.pone.0144924; PMCID=PMC4692263;
RA   Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K.,
RA   Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M.,
RA   Giefing M., Jarmuz-Szymczak M.;
RT   "Global miRNA expression profiling identifies miR-1290 as novel
RT   potential oncomiR in laryngeal carcinoma.";
RL   PLoS ONE 10:E0144924-E0144924(2015).
//
RX   PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733;
RA   Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A.,
RA   Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M.,
RA   Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.;
RT   "Drug-sensitivity screening and genomic characterization of 45
RT   HPV-negative head and neck carcinoma cell lines for novel biomarkers
RT   of drug efficacy.";
RL   Mol. Cancer Ther. 17:2060-2071(2018).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//
RX   PubMed=33802339; DOI=10.3390/cancers13051069; PMCID=PMC7959143;
RA   Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.;
RT   "Genotyping and characterization of HPV status, hypoxia, and
RT   radiosensitivity in 22 head and neck cancer cell lines.";
RL   Cancers (Basel) 13:1069.1-1069.12(2021).
//